Ishares Nasdaq Biotechnology Index Fund ETF News

Colony Group LLC lifted its stake in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 3.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,528 shares of the financial services providers stock after acquiring an additional 75 shares during the period. []

M&R Capital Management Inc. trimmed its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 7.1% during the third quarter, Holdings Channel.com reports. The firm owned 17,140 shares of the financial services providers stock after selling 1,317 shares during the period. M&R Capital Management Inc.s holdings in iShares Nasdaq Biotechnology ETF were worth $2,771,000 []

Mish's Economic Modern Family consists of 5 key sector ETFs, one major index ETF, and Bitcoin.  Bring them all together and you have an easy and quick way to look at the market, grasp overall trends,

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Smart Beta ETF report for IBB

Sector ETF report for IBB

In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.

CNBC's Morgan Brennan brings us Wednesday's edition of ETF Spotlight where they highlight the iShares Nasdaq Biotech ETF, with one of it's top holdings, Biogen, up 10% this year thanks to the prospect

Jared Holz, Oppenheimer, on whether the dip in biotech is an opportunity for investors. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Jeff Mills.

Despite suffering significant losses recently, biotechnology stocks and ETFs have seen some impressive gains over the last year or so, as coronavirus vaccines have propelled companies like Pfizer and

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

It could perhaps deliver a much bigger gain than 100%.

Let's take a look at some ETF areas that can be good investment options for September.

With so many stocks to choose from, trying to find the right ones can be a brutal task, which is why ETFs are so convenient. The post 7 Best ETFs to Buy to Cover a Broad Spectrum of Opportunities appe

ETFs that look at a subsector of biotech have significantly outperformed broader biotech funds this year.